Boehringer Ingelheim Faces Allegations Over Orange Book Patent Submissions
Pharmaceutical giant Boehringer Ingelheim has recently faced allegations of wrongfully submitting patents to the Orange Book, the FDA’s list of approved drug products with therapeutic equivalence evaluations. It is alleged that the company has been leveraging expired patents to maintain market monopoly. Spokesperson for the company, Jason Ginenthal, has rebutted these allegations. In a recent…